FindTrial
Sign In

Corneal collagen cross linking for treatment of infectious keratitis

Corneal collagen cross linking with photoactivated riboflavin [ PACK- CXL ] as adjunctive therapy for treatment of infectious keratitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201701001843366
Enrollment
Unknown
Registered
2016-10-30
Start date
2016-09-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious keratitis Infectious keratitis

Interventions

Medical treatment for infectious keratitis plus CXL
Medical treatment for infectious keratitis

Sponsors

Main contributor
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1- patients with clinically suspected infectious keratitis confirmed by both direct smears and cultures. 2- central corneal thickness of more than 400 microns with epithelium as measured by AS- OCT. 3- Infiltrates involving less than 250 microns depth of corneal thickness 4- patients more than 18 years

Exclusion criteria

Exclusion criteria: 1- Perforated corneal ulcers or impending perforation 2- Scleral involvement or near limbus by 1 mm 3- Total corneal involvement. 4- Evidence of endophthalmitis. 5- viral keratitis 6- known Allergy to study medications 7- Pregnancy 8- NO PL

Design outcomes

Primary

MeasureTime frame
Healing rate and period for study groups—

Secondary

MeasureTime frame
Uncorrected and best corrected visual acuity (UCVA and BCVA) for study groups—

Countries

Egypt

Contacts

Public ContactMohammed Tawfeek

Assistant lecturer

Dr_mahdy_1984@yahoo.com00201228898496

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026